Hiporfin (HpD) for fluorescence-guided resection of recurrent glioblastoma: diagnostic accuracy and feasibility of an integrated photodynamic strategy
- 1Sun Yat-sen University Cancer Center
Abstract
BackgroundHematoporphyrin derivative (HpD, Hiporfin) is used for photodynamic therapy (PDT) of solid tumors but had never been evaluated for fluorescence-guided resection (FGR) in glioma. We assessed Hiporfin fluorescence accuracy against histopathology in recurrent glioblastoma (rGBM) and the feasibility of adding cavity PDT to FGR.
MethodsIn this prospective single-arm study, adults with rGBM received a single preoperative intravenous Hiporfin dose of 5 mg/kg before FGR under blue-light excitation and 630-nm cavity PDT. Intraoperative fluorescence assessment was the index test and histopathology the reference standard. Specimen-level diagnostic accuracy was pooled with bivariate random-effects modeling.
ResultsOf 63 specimens, 35 were true positive, 7 false positive, 8 false negative and 13 true negative. Pooled sensitivity was 0.751 (95% confidence interval 0.600-0.858) and specificity 0.606 (0.407-0.775); the crude positive predictive value was 0.833 (0.694-0.917) and the negative predictive value 0.619 (0.409-0.792). All seven false-positive specimens were peritumoral tissue and the eight false negatives were non-fluorescent tumor. FGR combined with cavity PDT was completed in all six patients without new neurological deficits.
ConclusionsHiporfin fluorescence identified rGBM with moderate accuracy: fluorescent regions were likely tumor, while non-fluorescent tissue often still contained tumor. The main source of error was peritumoral tissue of the treated cavity, and not the drug or the optics.
Hiporfin is a new fluorescence agent for glioma. One drug provides both fluorescence guidance during resection and immediate cavity PDT.
Key PointsO_LIHiporfin fluorescence in recurrent glioblastoma: sensitivity 0.75, specificity 0.61. C_LIO_LIFluorescence predicted tumor with PPV 0.83, but its absence had NPV 0.62. C_LIO_LIFirst specimen-level accuracy estimated for Hiporfin fluorescence in recurrent glioblastoma. C_LI
Importance of the StudyHiporfin (hematoporphyrin derivative) is used for photodynamic therapy of solid tumors, but its fluorescence had not been characterized in the operative field. We provide the first clinical fluorescence-guided resection data for this agent in glioma and pair it with immediate cavity photodynamic therapy in a single procedure. In this prospective six-patient series, pooled sensitivity was 0.75 and specificity 0.61, so more than a third of non-fluorescent specimens still contained tumor while every false-positive specimen was peritumoral tissue. That failure mode is intrinsic to reoperation in a treated cavity and not to the drug or the optics. The workflow was completed in every patient without new deficit; the one patient with both a newly diagnosed and a recurrent lesion suggests greater potential for Hiporfin in newly diagnosed glioblastoma, which warrants prospective evaluation.
Related
- Cytokine-induced killer cells combined with temozolomide suppress glioblastoma progression in an orthotopic model and demonstrate clinical feasibility in recurrent glioblastoma
- A prospective cross-sectional diagnostic feasibility study: musculoskeletal ultrasound for pediatric bone age evaluation
- Integrated 3D light sheet and 2D multiplex imaging for deep histological characterization of somatic mouse glioblastoma
- Prospective Case Series to Determine the Feasibility, Diagnostic Yield and Safety of Performing EBUS Guided Trans‐Bronchial Mediastinal Cryobiopsy (EBUS‐TBMC) of Lymph Nodes Using 1.1 mm Cryoprobe Through a Working Channel of Linear EBUS Bronchoscope Versus Conventional En‐Bloc Cryobiopsy
- Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study
BibTeX
@misc{he2026hiporfin,
title = {{Hiporfin (HpD) for fluorescence-guided resection of recurrent glioblastoma: diagnostic accuracy and feasibility of an integrated photodynamic strategy}},
author = {Z. He and G. Zhang and C. Wang and L. Wu and W. Hu and H. Duan and Y. Chen and J. Lu and Z. Yuan and X. Zhang and Y. Mou},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.07.26364687},
url = {https://www.medrxiv.org/content/10.64898/2026.10.07.26364687v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Hiporfin (HpD) for fluorescence-guided resection of recurrent glioblastoma: diagnostic accuracy and feasibility of an integrated photodynamic strategy
AU - Z. He
AU - G. Zhang
AU - C. Wang
AU - L. Wu
AU - W. Hu
AU - H. Duan
AU - Y. Chen
AU - J. Lu
AU - Z. Yuan
AU - X. Zhang
AU - Y. Mou
PY - 2026
DA - 2026/10/07
PB - medRxiv
DO - 10.64898/2026.10.07.26364687
UR - https://www.medrxiv.org/content/10.64898/2026.10.07.26364687v1
AB - BackgroundHematoporphyrin derivative (HpD, Hiporfin) is used for photodynamic therapy (PDT) of solid tumors but had never been evaluated for fluorescence-guided resection (FGR) in glioma. We assessed Hiporfin fluorescence accuracy against histopathology in recurrent glioblastoma (rGBM) and the feasibility of adding cavity PDT to FGR. MethodsIn this prospective single-arm study, adults with rGBM received a single preoperative intravenous Hiporfin dose of 5 mg/kg before FGR under blue-light excitation and 630-nm cavity PDT. Intraoperative fluorescence assessment was the index test and histopathology the reference standard. Specimen-level diagnostic accuracy was pooled with bivariate random-effects modeling. ResultsOf 63 specimens, 35 were true positive, 7 false positive, 8 false negative and 13 true negative. Pooled sensitivity was 0.751 (95% confidence interval 0.600-0.858) and specificity 0.606 (0.407-0.775); the crude positive predictive value was 0.833 (0.694-0.917) and the negative predictive value 0.619 (0.409-0.792). All seven false-positive specimens were peritumoral tissue and the eight false negatives were non-fluorescent tumor. FGR combined with cavity PDT was completed in all six patients without new neurological deficits. ConclusionsHiporfin fluorescence identified rGBM with moderate accuracy: fluorescent regions were likely tumor, while non-fluorescent tissue often still contained tumor. The main source of error was peritumoral tissue of the treated cavity, and not the drug or the optics. Hiporfin is a new fluorescence agent for glioma. One drug provides both fluorescence guidance during resection and immediate cavity PDT. Key PointsO_LIHiporfin fluorescence in recurrent glioblastoma: sensitivity 0.75, specificity 0.61. C_LIO_LIFluorescence predicted tumor with PPV 0.83, but its absence had NPV 0.62. C_LIO_LIFirst specimen-level accuracy estimated for Hiporfin fluorescence in recurrent glioblastoma. C_LI Importance of the StudyHiporfin (hematoporphyrin derivative) is used for photodynamic therapy of solid tumors, but its fluorescence had not been characterized in the operative field. We provide the first clinical fluorescence-guided resection data for this agent in glioma and pair it with immediate cavity photodynamic therapy in a single procedure. In this prospective six-patient series, pooled sensitivity was 0.75 and specificity 0.61, so more than a third of non-fluorescent specimens still contained tumor while every false-positive specimen was peritumoral tissue. That failure mode is intrinsic to reoperation in a treated cavity and not to the drug or the optics. The workflow was completed in every patient without new deficit; the one patient with both a newly diagnosed and a recurrent lesion suggests greater potential for Hiporfin in newly diagnosed glioblastoma, which warrants prospective evaluation.
ER -